Poolbeg Pharma Future Growth

Future criteria checks 0/6

Poolbeg Pharma's earnings are forecast to decline at 20.9% per annum. EPS is expected to decline by 18.9% per annum.

Key information


Earnings growth rate


EPS growth rate

Pharmaceuticals earnings growth27.6%
Revenue growth raten/a
Future return on equity-318.3%
Analyst coverage


Last updated30 Apr 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

OTCPK:POLB.F - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: POLB.F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: POLB.F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: POLB.F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if POLB.F's revenue is forecast to grow faster than the US market.

High Growth Revenue: POLB.F is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: POLB.F is forecast to be unprofitable in 3 years.

Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.